1Hurst SA, Hartzfeld KM, DelPriore G, et al. Occult myometrial recur- rence after progesterone therapy to preserve fertility in a young patient with endometrial cancer [ J ]. Obstet Gyneco1,2008,89 ( 3 ) : 1 - 3.
2Park JC ,Cho CH ,Rhec JH. A successful live birth through in vitrofer- tilization program after conservative treatment of FIGO grade I endom- etrial cancer[ J ]. J Korean Med Sci,2006,21 ( 3 ) : 567 - 571.
3Chiva L, Iapuente F, Gonz lez - Cortijo L, et al. Sparing fertility in young patients with endometrial cancer[ J]. Gynecol Onco1,2008,111 Suppl 2 : 101 - 104.
4Yu M, Yang JX, Wu M, et al. Fertility - preserving treatment in young women with well - differentiated endometrial cancer and severe atypi- cal hyperplasia of endometrium [ J ]. Fertil Steril, 2009,92 : 2122 - 2124.
5Dursun P, Erkanli S, G zel AB, et al. A Turkish Gynecologic Oneology Group study of fertility - sparing treatment for early - stage endome- trial cancer[ J]. Int J Gynaecol Obstet,2012 ,119 :270 - 273.
6Cade TJ,Quinn MA,McNally OM,et 81. Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment? [ J]. IntJ Gynecol Cancer,2010,20 : 1166 - 1169.
8Kalogiannidis I, Agorastos T. Conservative management of young pa-tients with endometrial highly -differentiated adenocarcinoma[ J]. J Obstet Gynaeco1,2011,31 : 13 - 17.
9Yu M, Yang JX, Wu M,et al. Fertility -preserving treatment in young women with well - differentiated endometrial carcinoma and severe a- typical hyperplasia of endometrium [ J ]. Fertil Steril, 2009,92 : 2122 -2124.
10Kim MK, Yoon BS, Park H, et al. Conservative treatment with me- droxyprogesterone acetate plus levonorgestre| intrauterine system for early - stage eudometrial cancer in young women:pilot study[ J ]. Int J Gynecol, Cancer,2011,21:673 - 677.
二级参考文献59
1Ryan PD, Goss PE. Adjuvant hormonal therapy in pefi and postm- enopausal breast cancer [ J ]. Oncologist, 2006, 11 ( 7 ) : 11718 - 11731.
2The Breast International Group (BIG) 1 -98 Collaborative Group. A comparison of letrazole and tamoxifen in postmenopausal women with early breast cancer [ J ]. N Engl J Med, 2005,353 ( 26 ) : 2747 - 2757.
3Ito K, Utsunomiya H, Niikvra H,et al. Inhibition of estrogen actions in human gynecological malignancies: new aspects of endocrine thera- py for endometrial cancer and ovarian cancer[ J]. Mol Cell Endocri- nol, (2011), doi:10. 1016/j. mce. 2010. 11. 023.
4Liang YJ, Hao Q, Wu YZ, et al. Aromatase inhibitor letrozole in syn- ergy with curcumin in the inhibition of xenografted endometrial carci- noma growth [ J ]. Int J Gynecol Cancer, 2009,19 (7) : 1248 - 1252.
5Agorastos T, Vaitsi V, Pantazis K. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women [ J ]. Eur J Obstet Gynecol Reprod Biol, 2005,118 (2) :239 - 240.
6Stilwill SE, Cooper BC. Resolution of endometfial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report[ J ]. J Reprod Med,2007,52 ( 10 ) :979 - 980.
7Garuti G, Cellani F. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors [ J ]. Gynecol Oncol, 2006,103(2) :599 -603.
8Barker LC, Brand IR, Crawford SM,et al. Sustained effect of the aro- matase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma [ J ]. Curr Med Res Opin,2009,25(5) :1105 -1109.
9Berstein L. Aromatase and comparative response to its inhibitors in two types of endometrial cancer[J]. J Steroid Biochem Mol Biol, 2005,95 (1 -5) :71 -74.
10Bershten LM, Danilova MA, Kovalevski AIu, et al. Criteria for evalu- ating the effectiveness of aromatase inhibitors in the neoadjuvant treat- ment of patients with endometrial carcinoma[J]. Vopr Onkol,2009, 55(3) :314 -318.
